1.

Structure and Functions of Hemoglobin

I. Introduction
Hemoglobin (Hb) is a conjugated protein (metalloprotein)
found in red blood cells. Its primary role is the transport of
oxygen from the lungs to the tissues and carbon dioxide from
the tissues back to the lungs.
II. Structure of Hemoglobin
The structure can be divided into two main components: Heme
(Prosthetic group) and Globin (Protein part).
A. The Heme Part
* Heme is an Iron-porphyrin complex.
* It consists of a Protoporphyrin IX ring with a central Ferrous
iron (Fe^{2+}).
* The Fe^{2+} has 6 coordination bonds:
* 4 bonds with Nitrogen atoms of the pyrrole rings.
* 1 bond with the Proximal Histidine (F8) of the globin chain.
* 1 bond is available for Oxygen binding.
B. The Globin Part
* Hb is a tetramer (2 \alpha and 2 \beta chains in adults).
* \alpha-chain: 141 amino acids.
* \beta-chain: 146 amino acids.
* The chains are held together by non-covalent interactions
(hydrophobic, ionic, and hydrogen bonds).
C. Quaternary Structure (T and R States)
* T-form (Tense): Low oxygen affinity. Occurs in deoxygenated
Hb.
* R-form (Relaxed): High oxygen affinity. Occurs when oxygen
binds, breaking certain salt bridges.
III. Functions of Hemoglobin
| Function | Description |
|---|---|
| Oxygen Transport | Each Hb molecule can carry 4 molecules
of O_2. This exhibits Cooperativity (Sigmoid curve). |
| CO_2 Transport | Transports CO_2 as Carbaminohemoglobin
(binds to the N-terminus of globin, not heme). |
| Buffering Action | Hb acts as a powerful buffer in the blood
due to its Histidine residues, maintaining blood pH. |
| Nitric Oxide (NO) Transport | Hb can bind NO, a potent
vasodilator, helping in the regulation of vascular tone. |
IV. Clinical Significance (For Extra Marks)
* Anemia: A decrease in Hb concentration leads to reduced
oxygen-carrying capacity.
* Glycated Hemoglobin (HbA_{1c}): In chronic hyperglycemia
(Diabetes), glucose binds to Hb. It is used to monitor long-term
blood sugar levels (Ref: < 5.7%).
* Carbon Monoxide Poisoning: CO has 200x higher affinity for
Hb than O_2, forming Carboxyhemoglobin, which is toxic.
V. Essential Diagram for Exam
> Draw This: A simple schematic showing 4 circles (\alpha_1, \
alpha_2, \beta_1, \beta_2). Inside each, draw a small square
representing "Heme." Show O_2 binding to the square. Label
the "Heme-Heme interaction" and the "Proximal Histidine"
attachment.

I. Comprehensive Structure of Hemoglobin

1. The Quaternary Arrangement (The Tetramer)
Adult Hemoglobin (HbA_1) is a symmetric dimer of dimers. It is
composed of two identical \alpha\beta dimers ((\alpha\beta)_1
and (\alpha\beta)_2).
* Strong Interactions: Within each dimer (\alpha_1\beta_1),
amino acids are held by strong hydrophobic interactions.
* Weak Interactions: The two dimers are held together by
polar hydrogen bonds and ionic bonds (salt bridges). These
weak bonds allow the dimers to move with respect to each
other.
2. The Heme Microenvironment (The "Heme Pocket")
Heme is tucked into a hydrophobic pocket between the E and F
helices of the globin chain.
* The Iron (Fe^{2+}): Must remain in the Ferrous state to bind
O_2. If oxidized to Ferric (Fe^{3+}), it becomes Methemoglobin,
which cannot carry O_2.
* Proximal Histidine (His F8): Directly binds to the 5th
coordination position of the Iron.
* Distal Histidine (His E7): Does not bind the iron directly.
Instead, it acts as a "gatekeeper," creating a steric hindrance
that prevents Carbon Monoxide (CO) from binding
perpendicularly (which would be too strong) and forces O_2 to
bind at an angle.
II. Molecular Mechanism of Oxygen Binding
1. The T-State vs. R-State (The Cooperativity Model)
* T (Tense) State: The "deoxy" form. Multiple salt bridges exist
between the \alpha\beta dimers. It has a low affinity for O_2.
* R (Relaxed) State: The "oxy" form. Binding of O_2 ruptures
the salt bridges. It has a high affinity for O_2.
2. Piston-like Movement
When O_2 binds to the iron atom, the iron (which was slightly
outside the plane of the porphyrin ring) is pulled into the plane.
This pulls the Proximal Histidine, which moves the entire F-
helix. This structural shift is transmitted to the other subunits,
making it easier for them to bind O_2. This is called Positive
Cooperativity.
III. Detailed Functions & Oxygen Dissociation Curve (ODC)
1. Oxygen Transport & The Sigmoid Curve
Hb shows a Sigmoid (S-shaped) curve, unlike Myoglobin
(Hyperbolic). This allows Hb to be saturated in the lungs (high
pO_2) and effectively unload O_2 in the tissues (low pO_2).
2. The Bohr Effect (Regulation)
This is crucial for your essay. In tissues, CO_2 and H^+ levels are
high.
* These ions bind to Hb (at the globin part, not the heme).
* This stabilizes the T-state, shifting the ODC to the Right.
* Result: Hb releases O_2 more easily to the working tissues.
3. Role of 2,3-BPG
2,3-Bisphosphoglycerate is a "negative effector." It binds to the
central cavity of the deoxy-Hb tetramer and cross-links the \
beta-chains. This stabilizes the T-state and reduces oxygen
affinity, helping O_2 unloading in chronic hypoxia or at high
altitudes.
IV. Clinical Significance (The "10/10" Section)
* Methemoglobinemia: Caused by sulfonamides or deficiency
of NADH-methemoglobin reductase. Blood looks "chocolate-
colored." Treated with Methylene Blue.
* Carbon Monoxide Poisoning: CO binds 200 times more tightly
than O_2. It not only blocks O_2 binding but also shifts the ODC
to the Left, preventing the remaining O_2 from being released
to tissues (double-lethal effect).
* Pulse Oximetry: Clinically measures the ratio of Oxy-Hb to
Deoxy-Hb based on light absorption.
V. Recommended Exam Flowchart:
> Hb Structure \rightarrow Heme + Globin \rightarrow O_2
Binding \rightarrow Conformational Change (T to R) \rightarrow
Sigmoid ODC \rightarrow Tissue Delivery (Bohr Effect).
2. Heme Synthesis, Regulation, and Porphyrias
I. Introduction
Heme is an iron-protoporphyrin complex. Synthesis occurs in
almost all mammalian cells, but primarily in the Bone Marrow
(for Hemoglobin) and Liver (for Cytochromes).
* Location: Part of the pathway occurs in the Mitochondria and
part in the Cytosol.
* Starting Materials: Succinyl CoA (from TCA cycle) and Glycine
(amino acid).
II. The Heme Synthesis Pathway (Flowchart)
This is the "Bread and Butter" of your answer. Draw this clearly:
* Mitochondria: Glycine + Succinyl CoA \xrightarrow{ALA\
synthase} \delta-Aminolevulinic acid (ALA). (Requires Pyridoxal
Phosphate/Vit B6).
* Cytosol: 2 molecules of ALA \xrightarrow{ALA\ dehydratase}
Porphobilinogen (PBG).
* Cytosol: 4 molecules of PBG \xrightarrow{PBG\ deaminase}
Hydroxymethylbilane.
* Cytosol: Hydroxymethylbilane \
xrightarrow{Uroporphyrinogen\ III\ synthase}
Uroporphyrinogen III.
* Cytosol: Uroporphyrinogen III \xrightarrow{Decarboxylase}
Coproporphyrinogen III.
* Mitochondria: Coproporphyrinogen III \xrightarrow{Oxidase}
Protoporphyrinogen IX.
* Mitochondria: Protoporphyrinogen IX \xrightarrow{Oxidase}
Protoporphyrin IX.
* Final Step: Protoporphyrin IX + Fe^{2+} \
xrightarrow{Ferrochelatase} HEME.
III. Regulation of Heme Synthesis
The primary regulatory enzyme is ALA Synthase (ALAS).
* End-product Inhibition: Heme acts as a feedback inhibitor of
ALAS.
* Repression: Heme represses the synthesis of the ALAS
enzyme at the genetic level.
* Drugs/Steroids: Drugs metabolized by Cytochrome P450 (like
Phenobarbital) consume heme. This decreases heme levels,
releasing the "brakes" on ALAS, leading to increased heme
synthesis (This is why such drugs trigger Porphyria attacks).
* Glucose Effect: High glucose levels repress ALAS (this is why
IV glucose is used to treat acute attacks).
IV. Porphyrias: Clinical Note
Porphyrias are a group of metabolic disorders caused by a
deficiency of enzymes in the heme pathway, leading to the
accumulation of toxic intermediates.
Classification Table (The "Topper's Table")
| Type of Porphyria | Deficient Enzyme | Major Findings /
Symptoms |
|---|---|---|
| Acute Intermittent Porphyria (AIP) | PBG Deaminase |
Abdominal pain, Neuropsychiatric symptoms, Port-wine
colored urine (on standing). No Photosensitivity. |
| Porphyria Cutanea Tarda (PCT) | Uroporphyrinogen
Decarboxylase | Most common type. Photosensitivity, skin
blistering, fragile skin. Associated with Hep C/Alcohol. |
| Congenital Erythropoietic Porphyria (CEP) |
Uroporphyrinogen III Synthase | Extreme photosensitivity, red-
stained teeth (Erythrodontia), hairy skin. |
| Variegate Porphyria | Protoporphyrinogen Oxidase | Mix of
skin photosensitivity and neurological symptoms. |
V. Key Clinical Findings in Porphyria
* Neurological: "Pain in the brain and pain in the abdomen."
Autonomic neuropathy.
 * Dermatological: Accumulation of porphyrins in the skin leads
to oxygen radical formation when exposed to UV light, causing
Photosensitivity and scarring.
* Urine: Colorless when fresh, but turns dark red/port-wine
color upon standing due to oxidation of PBG to Porphobilin.
VI. Important Exam Diagrams
* The "Compartment" Diagram: Draw a large cell. Draw a
Mitochondria inside. Show the steps moving out to the Cytosol
and then moving back into the Mitochondria for the finish.
* Regulation Loop: Draw ALAS \rightarrow Heme. Draw a
dashed line with a minus sign (—) from Heme back to ALAS.

1. Formation of \delta-Aminolevulinic Acid (ALA)

* Location: Mitochondria.
* Enzyme: ALA Synthase (ALAS) (Rate-limiting step).
* Reaction: Succinyl CoA + Glycine \rightarrow ALA.
* Cofactor: Pyridoxal Phosphate (Vitamin B_6).
2. Synthesis of Porphobilinogen (PBG)
* Location: Cytosol (ALA moves out of mitochondria).
* Enzyme: ALA Dehydratase (also called PBG Synthase).
* Reaction: 2 molecules of ALA condense to form 1
monopyrrole (PBG).
* Note: This enzyme is highly sensitive to Lead poisoning.
3. Formation of Hydroxymethylbilane (Pre-uroporphyrinogen)
* Location: Cytosol.
* Enzyme: Uroporphyrinogen I Synthase (or PBG Deaminase).
* Reaction: 4 molecules of PBG condense into a linear
tetrapyrrole.
4. Cyclization to Uroporphyrinogen III
* Location: Cytosol.
* Enzyme: Uroporphyrinogen III Co-synthase.
* Reaction: The linear tetrapyrrole closes into a ring. This
creates the asymmetric "Type III" isomer required for heme.
5. Decarboxylation to Coproporphyrinogen III
* Location: Cytosol.
* Enzyme: Uroporphyrinogen Decarboxylase.
* Reaction: Acetate groups are converted to Methyl groups.
6. Oxidation to Protoporphyrinogen IX
* Location: Mitochondria (Substrate moves back in).
* Enzyme: Coproporphyrinogen Oxidase.
* Reaction: Propionate groups are converted to Vinyl groups.
7. Formation of Protoporphyrin IX
* Location: Mitochondria.
* Enzyme: Protoporphyrinogen Oxidase.
* Reaction: Oxidation of the ring to create a conjugated
double-bond system (giving it color).
8. Final Incorporation of Iron (Heme Formation)
* Location: Mitochondria.
* Enzyme: Ferrochelatase (Heme Synthase).
* Reaction: Ferrous Iron (Fe^{2+}) is inserted into the center of
Protoporphyrin IX.

3. Degradation of Heme and Fate of its Products

I. Introduction
The average lifespan of an RBC is 120 days. Aged RBCs are
trapped and destroyed in the Reticuloendothelial (RE) system,
primarily the Spleen and Liver.
II. Step-by-Step Degradation Pathway
1. Formation of Biliverdin (In the Macrophage/Spleen)
The heme ring is broken open.
* Enzyme: Heme Oxygenase (Requires O_2 and NADPH).
* Products: Biliverdin (green pigment), Carbon Monoxide (CO),
and Ferrous Iron (Fe^{2+}).
* Note: This is the only endogenous source of CO in the human
body.
2. Formation of Bilirubin (In the Macrophage)
* Enzyme: Biliverdin Reductase (Requires NADPH).
* Product: Unconjugated Bilirubin (UCB). This is water-
insoluble and toxic to the brain.
3. Transport to the Liver
* Since UCB is lipid-soluble, it cannot travel alone in the blood.
It binds non-covalently to Albumin.
* Clinical Pearl: Certain drugs (like Aspirin) can displace
bilirubin from albumin, leading to Kernicterus in neonates.
4. Hepatic Uptake and Conjugation
* Uptake: Bilirubin is taken up by hepatocytes via facilitated
diffusion (using Ligandin).
* Conjugation: To make it water-soluble, two molecules of
Glucuronic acid are added.
* Enzyme: UDP-Glucuronosyltransferase (UGT).
* Product: Bilirubin Diglucuronide (Conjugated Bilirubin).
5. Excretion into Bile
* Conjugated bilirubin is actively transported into the bile
canaliculi. This is the rate-limiting step of hepatic bilirubin
metabolism.
6. Fate in the Intestine
* In the colon, bacterial enzymes (deconjugases) remove the
glucuronic acid.
* Bilirubin is converted into Urobilinogen (colorless).
* Fate of Urobilinogen:
* Stercobilin: Most is oxidized to Stercobilin and excreted in
feces (gives feces its brown color).
* Enterohepatic Circulation: A small portion (20%) is
reabsorbed into the portal blood.
* Urobilin: A tiny fraction of reabsorbed urobilinogen reaches
the kidneys and is excreted as Urobilin (gives urine its yellow
color).
III. Summary Table of Degradative Products
| Product | Fate/Significance |
|---|---|
| Iron (Fe^{2+}) | Recycled; stored as Ferritin or transported by
Transferrin. |
| Globin | Broken down into Amino Acids for reuse in protein
synthesis. |
| Carbon Monoxide | Exhaled through the lungs. |
| Bilirubin | Excreted via bile/feces/urine. |
IV. Clinical Significance (The 10/10 Touch)
* Jaundice (Icterus): Occurs when serum bilirubin exceeds 2
mg/dL.
* Van Den Bergh Reaction:
* Direct Positive: Indicates Conjugated Hyperbilirubinemia
(e.g., Obstruction).
* Indirect Positive: Indicates Unconjugated
Hyperbilirubinemia (e.g., Hemolysis).
* Crigler-Najjar & Gilbert Syndrome: Genetic defects in the
conjugation enzyme (UGT).
V. Essential Exam Diagram
> The "Spleen-Liver-Gut" Axis: Draw three boxes.
> * Spleen: Heme \rightarrow Bilirubin.
> * Blood: Bilirubin + Albumin.
> * Liver: Conjugation.
> * Gut: Urobilinogen \rightarrow Stercobilin.

3. Detailed Degradation of Heme and Bilirubin Metabolism

I. Stage 1: The Reticuloendothelial (RE) System (Spleen/Bone
Marrow)
When RBCs reach the end of their 120-day lifespan, they are
sequestered in the splenic sinusoids.
* Heme Oxygenase System: This is a multi-enzyme complex
located in the Microsomes.
* It requires Molecular Oxygen (O_2) and NADPH.
* The Reaction: It adds a hydroxyl group to the \alpha-
methene bridge between pyrrole rings I and II.
* The Break: The ring opens, releasing Carbon Monoxide (CO)
and Ferrous Iron (Fe^{2+}).
* Product: Biliverdin (a linear tetrapyrrole, green in color).
* Biliverdin Reductase:
* Reduces the central methene bridge of biliverdin.
 * Requires NADPH.
* Product: Bilirubin (orange-yellow). This is Unconjugated
Bilirubin (UCB).
II. Stage 2: Transport in Plasma
* The Albumin Bond: UCB is virtually insoluble in water. It binds
to Albumin at two sites (one high-affinity, one low-affinity).
* Clinical Importance: This "Bilirubin-Albumin Complex" is too
large to pass through the glomerular filtrate, so unconjugated
bilirubin never appears in urine (Acholuric Jaundice).
III. Stage 3: Hepatic Phase (The 3 'U's: Uptake, UDP-
Conjugation, Unloading)
* Uptake: At the sinusoidal surface of the hepatocyte, bilirubin
dissociates from albumin. It enters the liver cell via facilitated
diffusion mediated by organic anion transporting polypeptides
(OATP). Inside, it binds to Ligandin (Y-protein) to prevent it
from leaking back into the blood.
* Conjugation: This occurs in the Smooth Endoplasmic
Reticulum.
* Enzyme: Bilirubin-UDP-Glucuronosyltransferase (UGT1A1).
* Process: Two molecules of Glucuronic acid (from UDP-
Glucuronic acid) are attached to the propionic acid side chains
of bilirubin.
 * Product: Bilirubin Diglucuronide (Conjugated Bilirubin/CB).
It is now water-soluble.
* Excretion (Secretory Phase): CB is transported against a steep
concentration gradient into the bile canaliculi.
* Transporter: MRP2 (Multidrug Resistance-associated
Protein 2).
* Significance: This is the Rate-Limiting Step of the entire
hepatic metabolism.
IV. Stage 4: Intestinal Phase and Excretion
* Deconjugation: In the lower intestine, bacterial \beta-
glucuronidases strip away the glucuronic acid.
* Reduction: Bacteria reduce bilirubin into a group of colorless
compounds called Urobilinogens.
The Three Fates of Urobilinogen:
* Fecal Excretion (80%): Most urobilinogen is oxidized by
intestinal flora into Stercobilin (brown pigment), which is
excreted in feces.
* Enterohepatic Circulation (20%): A portion is reabsorbed into
the portal vein and returns to the liver to be re-excreted.
* Urinary Excretion (2%): A tiny fraction escapes hepatic
uptake, enters systemic circulation, reaches the kidneys, and is
oxidized to Urobilin (yellow pigment) and excreted.
V. Summary of Bilirubin Fractions (For Differential Diagnosis)
| Property | Unconjugated (Indirect) | Conjugated (Direct) |
|---|---|---|
| Water Solubility | Insoluble | Soluble |
| Affinity to Albumin | High | Low/None |
| Renal Excretion | Absent (Acholuric) | Present (Bilirubinuria) |
| Toxicity | High (can cross Blood-Brain Barrier) | Low |
| Van Den Bergh | Indirect Positive | Direct Positive |
VI. Detailed Clinical Significance
* Kernicterus: In newborns, if UCB levels exceed 20 mg/dL, it
crosses the Blood-Brain Barrier and deposits in the Basal
Ganglia, causing permanent neurological damage.
* Phototherapy: Used in neonatal jaundice. Blue-green light
(420–470 nm) converts bilirubin into Lumirubin (a water-
soluble structural isomer) that can be excreted without
conjugation.
4. Hemoglobinopathies
I. Introduction
Hemoglobinopathies are a group of genetic disorders caused
by:
* Qualitative defects: Synthesis of structurally abnormal
hemoglobin (e.g., Sickle Cell Anemia).
* Quantitative defects: Reduced synthesis of normal globin
chains (e.g., Thalassemia).
II. Sickle Cell Anemia (HbS)
This is the most important qualitative hemoglobinopathy. It is
an autosomal recessive disorder.
1. Molecular Basis (The "Gold Standard" Answer)
* Point Mutation: A single base substitution (SNP) in the \beta-
globin gene.
* Substitution: Glutamic acid (polar/acidic) is replaced by
Valine (non-polar/hydrophobic) at the 6th position of the \
beta-chain.
* Notation: \alpha_2 \beta_2^{6 Glu \to Val}.
2. Pathogenesis (Sickling Phenomenon)
* In the Deoxygenated state (T-state), the hydrophobic Valine
at position 6 becomes exposed.
 * This creates a "sticky patch" on the surface of the \beta-
chain.
* These patches interact with complementary sites on other
HbS molecules, leading to Polymerization.
* Long, insoluble fibers form, distorting the RBC into a Sickle
shape.
3. Clinical Consequences
* Vaso-occlusive Crises: Sickled cells are rigid and block
capillaries, causing tissue hypoxia and extreme pain (Infarction).
* Hemolytic Anemia: Sickled cells are fragile and destroyed in
the spleen (Lifespan reduced from 120 to ~15 days).
* Autosplenectomy: Repeated splenic infarcts lead to a
shrunken, non-functional spleen.
III. Thalassemia
These are quantitative defects characterized by the decreased
or absent synthesis of one of the globin chains.
1. \alpha-Thalassemia
* Defect: Decreased synthesis of \alpha-globin chains.
* Genetics: Usually caused by Gene Deletions on Chromosome
16 (each human has 4 \alpha-genes).
* Key Forms:
 * 1 Gene deleted: Silent carrier.
* 3 Genes deleted (HbH disease): \beta_4 tetramers form.
High oxygen affinity, useless for delivery.
* 4 Genes deleted (Hydrops Fetalis): \gamma_4 tetramers
form (Hb Bart's). Fatal in utero.
2. \beta-Thalassemia
* Defect: Decreased synthesis of \beta-globin chains.
* Genetics: Usually caused by Point Mutations (rather than
deletions) on Chromosome 11.
* Types:
* \beta-Thalassemia Minor (Trait): Heterozygous (\beta / \
beta^+). Usually asymptomatic.
* \beta-Thalassemia Major (Cooley’s Anemia): Homozygous (\
beta^0 / \beta^0). Severe anemia starts at 6 months of age
(when HbF switches to HbA).
3. Pathophysiology of \beta-Thalassemia Major
* \alpha-chain precipitation: Since \beta-chains are missing,
excess \alpha-chains accumulate and precipitate, damaging the
RBC membrane (Ineffective Erythropoiesis).
 * Skeletal Changes: Compensatory expansion of bone marrow
leads to "Crew-cut" appearance on X-ray and "Chipmunk
facies."
IV. Other Abnormal Hemoglobins (Brief Note)
* HbC: Glutamic acid replaced by Lysine at 6th position of \
beta-chain. Causes mild hemolytic anemia.
* HbE: Glutamic acid replaced by Lysine at 26th position of \
beta-chain. Common in SE Asia.
V. Laboratory Diagnosis (Topper's Corner)
| Feature | Sickle Cell Anemia | \beta-Thalassemia Major |
|---|---|---|
| Peripheral Smear | Sickle cells, Target cells | Microcytic
hypochromic, Target cells |
| Hb Electrophoresis | Presence of HbS | Increased HbF and
HbA2, absence/reduction of HbA1 |
| Special Test | Sickling test (using Sodium dithionite) |
Mentzer Index (MCV/RBC count) |
VI. Essential Exam Diagram: Electrophoresis
> Draw This: A diagram of an electrophoresis gel. Label the
lanes: Normal (HbA1), Sickle Trait (HbA1 + HbS), and Sickle Cell
Disease (HbS only). Show that HbA moves fastest toward the
anode, while HbS moves slower (due to loss of negative charge
from Glutamate).

5. Jaundice (Icterus)
I. Definition
Jaundice is the yellowish discoloration of the skin, mucous
membranes, and sclera due to the deposition of bilirubin. It
becomes clinically detectable when total serum bilirubin
exceeds 2.0 mg/dL (Normal: 0.2–1.0 mg/dL).
II. Classification of Jaundice
Based on the site of the pathology, it is classified into three
types:
1. Pre-Hepatic (Hemolytic) Jaundice
* Cause: Excessive breakdown of RBCs (e.g., Sickle cell anemia,
Thalassemia, Malaria, Incompatible blood transfusion).
* Mechanism: The liver receives more bilirubin than it can
conjugate.
* Dominant Bilirubin: Unconjugated Bilirubin (UCB) increases.
2. Hepatic (Hepatocellular) Jaundice
* Cause: Damage to liver parenchyma (e.g., Viral Hepatitis,
Alcoholic Cirrhosis, Toxic drugs).
* Mechanism: The liver's ability to uptake, conjugate, and
secrete bilirubin is impaired.
* Dominant Bilirubin: Both UCB and Conjugated Bilirubin (CB)
increase.
3. Post-Hepatic (Obstructive) Jaundice
* Cause: Obstruction of the biliary tree (e.g., Gallstones,
Carcinoma of the head of the pancreas).
* Mechanism: Bilirubin is conjugated normally, but it cannot
reach the intestine and "regurgitates" back into the blood.
* Dominant Bilirubin: Conjugated Bilirubin (CB) increases.
III. The Van Den Bergh Reaction
This is a crucial biochemical test used to differentiate the types
of bilirubin.
* Direct Reaction: Conjugated bilirubin (water-soluble) reacts
immediately with Ehrlich’s diazo reagent.
* Indirect Reaction: Unconjugated bilirubin (water-insoluble)
reacts only after adding alcohol/methanol.
* Biphasic Reaction: Both types are present (Common in
Hepatic Jaundice).
IV. Differential Diagnosis Table (The "Topper's Choice")
Copy this table exactly for the exam to secure maximum marks.
| Feature | Pre-Hepatic | Hepatic | Post-Hepatic |
|---|---|---|---|
| Serum Bilirubin | Raised (UCB) | Raised (Both) | Raised (CB) |
| Van Den Bergh | Indirect Positive | Biphasic | Direct Positive |
| Urine Bilirubin | Absent (Acholuric) | Present | Present |
| Urine Urobilinogen | Increased | Decreased/Normal | Absent
|
| Fecal Stercobilin | Increased (Dark stools) | Decreased |
Absent (Clay colored) |
| Serum Enzymes | Normal ALT/AST | Very High ALT/AST | Very
High ALP/GGT |
V. Physiological Jaundice of the Newborn
* Occurrence: Seen in almost all infants on the 2nd–3rd day of
life.
* Reason: Transient deficiency of the enzyme UDP-
Glucuronosyltransferase and increased RBC breakdown.
* Treatment: Phototherapy (converts bilirubin to water-soluble
Lumirubin).
VI. Clinical Significance & Complications
* Pruritus (Itching): Common in Obstructive jaundice due to
deposition of bile salts in the skin.
* Steatorrhea: Fat malabsorption due to absence of bile in the
gut (Obstructive Jaundice).
* Kernicterus: In severe neonatal jaundice, UCB crosses the
blood-brain barrier, leading to permanent brain damage.
VII. Essential Flowchart for the Exam:
> Bilirubin Metabolism Map: Draw a flow from Heme \
rightarrow UCB (Blood) \rightarrow CB (Liver) \rightarrow Gut.
> * Draw a "Block" at the Blood stage for Hemolytic.
> * Draw a "Block" at the Liver stage for Hepatic.
> * Draw a "Block" at the Bile Duct stage for Obstructive.

Q1. Formation, Transport, and Fate of Bilirubin

1. Introduction
Bilirubin is the bile pigment formed from the catabolism of
Heme. It is a waste product that must be excreted because high
levels are toxic to the brain (Kernicterus).
2. Formation of Bilirubin
About 80-85% of bilirubin comes from the breakdown of
senescent (old) Red Blood Cells (RBCs) in the
Reticuloendothelial system (Spleen, Liver, Bone Marrow). The
remaining 15-20% comes from "ineffective erythropoiesis" or
other heme proteins like cytochromes.
The Process:
* Step 1: Heme is acted upon by Heme Oxygenase. This breaks
the porphyrin ring to form Biliverdin (green pigment).
* Step 2: Biliverdin is reduced by Biliverdin Reductase to form
Bilirubin (yellow-orange pigment).
> Note: This initial bilirubin is unconjugated, meaning it is
water-insoluble and lipophilic.
>
3. Transport in Blood
Since unconjugated bilirubin is insoluble in water, it cannot
travel alone in the plasma.
* It binds non-covalently to Albumin.
* This Bilirubin-Albumin Complex is too large to pass through
the glomerular filter of the kidney, which is why unconjugated
bilirubin never appears in urine.
4. Hepatic Phase (Uptake and Conjugation)
Once the complex reaches the liver:
* Uptake: Bilirubin dissociates from albumin and enters the
hepatocytes via a carrier-mediated protein called Organic Anion
Transporting Polypeptide (OATP). Inside the cell, it binds to
Ligandin (Y-protein) to prevent it from leaking back into the
blood.
* Conjugation: In the Smooth Endoplasmic Reticulum, the
enzyme UDP-Glucuronosyltransferase (UGT) adds two
molecules of glucuronic acid to bilirubin.
* This forms Bilirubin Diglucuronide (Conjugated Bilirubin).
* Significance: This makes bilirubin water-soluble and ready
for excretion.
5. Fate of Bilirubin (Excretion)
* Biliary Secretion: Conjugated bilirubin is actively secreted
into the bile canaliculi (the rate-limiting step).
* Intestinal Action: It enters the intestine, where bacterial
enzymes (β-glucuronidases) deconjugate it and reduce it to
Urobilinogen (colorless).
The Three Paths of Urobilinogen:
* Stercobilin: Most urobilinogen is oxidized to Stercobilin,
which gives feces its characteristic brown color.
 * Enterohepatic Circulation: A small portion (about 20%) is
reabsorbed into the portal blood and returns to the liver.
* Urobilin: A tiny fraction of the reabsorbed urobilinogen
bypasses the liver, enters systemic circulation, is filtered by the
kidneys, and oxidized to Urobilin, giving urine its yellow color.
Flowchart of Bilirubin Metabolism
Exam Tip: Mentioning the enzyme UDP-
Glucuronosyltransferase and the distinction between
conjugated (direct) and unconjugated (indirect) bilirubin is
crucial for securing full marks.

Q2. What is Porphyria?

1. Definition
Porphyrias are a group of metabolic disorders caused by a
partial deficiency of specific enzymes in the Heme Biosynthetic
Pathway. This leads to the abnormal accumulation and
increased excretion of porphyrins or their precursors (like ALA
and PBG).
2. Classification
They are broadly classified based on the primary site of
overproduction of porphyrin precursors:
 * Hepatic Porphyrias: Primarily affect the liver (e.g., Acute
Intermittent Porphyria).
* Erythropoietic Porphyrias: Primarily affect the bone marrow
(e.g., Congenital Erythropoietic Porphyria).
3. Detailed Explanation of Three Porphyrias
A. Acute Intermittent Porphyria (AIP)
This is the most common hepatic porphyria.
* Enzyme Deficient: Heme/PBG Deaminase (also known as
Uroporphyrinogen I Synthase).
* Accumulated Metabolites: Delta-aminolevulinic acid (ALA)
and Porphobilinogen (PBG).
* Clinical Features:
* Abdominal Pain: Severe, poorly localized pain.
* Neuropsychiatric symptoms: Confusion, psychosis, or
seizures.
* Port-wine Urine: Urine turns dark red/purple upon standing
due to oxidation of PBG.
* Note: Patients are NOT photosensitive.
B. Porphyria Cutanea Tarda (PCT)
The most common type of porphyria overall; it can be acquired
(alcohol, iron overload) or inherited.
* Enzyme Deficient: Uroporphyrinogen Decarboxylase.
* Accumulated Metabolite: Uroporphyrin.
* Clinical Features:
* Photosensitivity: The accumulated porphyrins react with
sunlight to form reactive oxygen species, causing skin damage.
* Skin Blisters: Fragile skin, vesicles, and scarring on sun-
exposed areas (hands/face).
* Hyperpigmentation: Darkening of the skin.
C. Congenital Erythropoietic Porphyria (Gunther’s Disease)
A rare, autosomal recessive erythropoietic porphyria.
* Enzyme Deficient: Uroporphyrinogen III Co-synthase.
* Accumulated Metabolites: Uroporphyrinogen I and
Coproporphyrinogen I (asymmetrical isomers).
* Clinical Features:
* Severe Photosensitivity: Leads to mutilation of fingers, nose,
and ears.
* Erythrodontia: Teeth fluoresce red under UV light due to
porphyrin deposition.
 * Hemolytic Anemia: Splenomegaly is common.
Summary Table for Exam Revision
| Porphyria | Enzyme Deficient | Metabolite in Urine | Key
Clinical Feature |
|---|---|---|---|
| AIP | PBG Deaminase | ALA & PBG | Neuropsychiatric +
Abdominal pain |
| PCT | Uroporphyrinogen Decarboxylase | Uroporphyrin | Skin
Blisters & Photosensitivity |
| Gunther's | Uroporphyrinogen III Co-synthase | Uroporphyrin
I | Red Teeth (Erythrodontia) |
4. General Treatment Principles
* Avoid Triggers: Drugs (Barbiturates), Alcohol, or Fasting.
* Hematin/Heme Arginate: Given to inhibit ALA Synthase (the
rate-limiting enzyme) via feedback inhibition.
* Glucose Loading: High carbohydrate diet helps suppress ALA
synthase.
The Mechanism of Accumulation in CEP (Gunther's Disease)
* The Normal Path:
Normally, the linear molecule Hydroxymethylbilane (HMB) is
acted upon by the enzyme Uroporphyrinogen III Co-synthase.
This enzyme does two things: it flips one of the rings and closes
the circle to form the Type III isomer (the one used for heme).
* The "Detour" (The Non-Enzymatic Step):
When Uroporphyrinogen III Co-synthase is deficient, HMB
starts to build up in the cell. HMB is chemically unstable.
Because it can't be converted to the Type III isomer fast
enough, it undergoes spontaneous (non-enzymatic) cyclization.
* The Result:
When it closes into a ring without the enzyme, it doesn't flip
the last ring correctly. It forms Uroporphyrinogen I (a
symmetric, "useless" isomer).
* The Accumulation:
The body cannot use the Type I isomer for heme synthesis.
Therefore, Uroporphyrinogen I (and its oxidized form,
Uroporphyrin I) accumulates in the blood, tissues, and teeth,
leading to the "Red Teeth" and severe photosensitivity you see
in patients.
Summary for your Exam
* Enzyme Deficient: Uroporphyrinogen III Co-synthase.
* Accumulated Product: Uroporphyrinogen I (and
Coproporphyrinogen I).
* Reason: Spontaneous, non-enzymatic ring closure of the
precursor (HMB) because it cannot be processed by the
deficient enzyme.
Q3: Synthesis and Regulation of Porphyrins
This question is a favorite for a 6-mark flow chart. To get full
marks, you must highlight the Rate-Limiting Step and the
Regulatory Mechanism.
1. Site of Synthesis
* Organ: Primarily the Liver (for cytochromes) and Erythroid
cells of Bone Marrow (for Hemoglobin).
* Cellular Location: It starts in the Mitochondria, moves to the
Cytosol, and finishes back in the Mitochondria. (Remember:
"M-C-M")
2. The Reaction Steps (Flowchart)
Step 1: The Regulatory Step (Mitochondria)
Succinyl CoA + Glycine \xrightarrow{\text{ALA Synthase (PLP
dependent)}} \delta-Aminolevulinic acid (ALA).
* Note: This requires Vitamin B6 (Pyridoxal Phosphate).
Step 2: Formation of PBG (Cytosol)
2 molecules of ALA condense to form Porphobilinogen (PBG).
* Enzyme: ALA Dehydratase (inhibited by Lead).
Step 3: Formation of HMB (Cytosol)
4 molecules of PBG condense to form Hydroxymethylbilane
(HMB).
* Enzyme: PBG Deaminase (Uroporphyrinogen I Synthase).
Step 4: Ring Closure (Cytosol)
HMB is converted to Uroporphyrinogen III.
* Enzyme: Uroporphyrinogen III Co-synthase.
Step 5 to 8: Final Modifications (Cytosol to Mitochondria)
Uroporphyrinogen III \to Coproporphyrinogen III \to
Protoporphyrinogen IX \to Protoporphyrin IX.
Step 9: Iron Insertion (Mitochondria)
Ferrous iron (Fe^{2+}) is added to Protoporphyrin IX to form
Heme.
* Enzyme: Ferrochelatase (also inhibited by Lead).
3. Regulation of Heme Synthesis
This is the most important part of the 6-mark answer. The main
control point is the first enzyme: ALA Synthase (ALAS).
* Feedback Inhibition: High levels of Heme act as a feedback
repressor. Heme decreases the synthesis and transport of ALAS
into the mitochondria.
* Induction by Drugs: Certain drugs (like Barbiturates or
Griseofulvin) induce the synthesis of Cytochrome P450. This
uses up heme, lowering its concentration. The lower heme level
"releases the brakes" on ALAS, increasing porphyrin production.
(This is why these drugs trigger Porphyria attacks!).
* Erythroid Regulation: In bone marrow, heme synthesis is
regulated by Iron availability and Erythropoietin, rather than
just feedback inhibition.

Q4. Unconjugated Hyperbilirubinemia

1. Definition
It is a condition characterized by an increase in the blood levels
of unconjugated (indirect) bilirubin (> 1.0 mg/dL). Because this
bilirubin is bound to albumin and is water-insoluble, it does not
appear in the urine (acholuric jaundice).
2. Pathophysiology
Unconjugated hyperbilirubinemia occurs due to one of three
main mechanisms:
* Excessive Production: Overwhelming the liver's ability to
conjugate.
* Reduced Hepatic Uptake: Failure of bilirubin to enter the
hepatocyte.
* Impaired Conjugation: Deficiency or absence of the enzyme
UDP-Glucuronosyltransferase (UGT).
3. Important Causes (The "Big Three")
A. Hemolytic Jaundice
* Cause: Excessive breakdown of RBCs (e.g., Sickle Cell Anemia,
Thalassemia, Malaria, or Rh incompatibility).
* Mechanism: Heme degradation produces more bilirubin than
the liver can "handle" (conjugate).
* Lab Findings: * ↑ Unconjugated Bilirubin.
* ↑ Urobilinogen in urine (since more conjugated bilirubin
eventually reaches the gut).
* Absent bilirubin in urine.
B. Physiological Jaundice of the Newborn
* Cause: Transient "immaturity" of the liver in neonates.
* Mechanism: Low activity of the enzyme UGT and increased
RBC turnover.
* Risk: If levels exceed 20 mg/dL, bilirubin can cross the blood-
brain barrier, causing Kernicterus (permanent brain damage).
* Treatment: Phototherapy (converts bilirubin into water-
soluble lumirubin).
C. Genetic Enzyme Deficiencies
* Crigler-Najjar Syndrome Type I: Total absence of UGT. Very
severe; usually fatal in infancy.
* Crigler-Najjar Syndrome Type II: Partial deficiency of UGT.
Less severe.
* Gilbert’s Syndrome: Mild, harmless reduction in UGT activity
(\sim 30\% of normal). Often discovered during stress or
fasting.
4. Diagnostic Lab Features
To score full marks, include this small table to show the
"Biochemical Profile":
| Feature | Finding |
|---|---|
| Serum Bilirubin | Total ↑ (Mainly Indirect/Unconjugated) |
| Van den Bergh Test | Indirect Positive |
| Urine Bilirubin | Absent (Acholuric) |
| Urine Urobilinogen | Increased |
| Fecal Stercobilin | Increased (Darker stools) |
5. Clinical Note: Kernicterus
Unlike conjugated bilirubin, unconjugated bilirubin is lipophilic.
It can cross the blood-brain barrier and deposit in the basal
ganglia, leading to toxic encephalopathy. This is a medical
emergency in neonates.

In this scenario, the liver can conjugate the bilirubin just fine,
but it cannot get it out of the liver or through the bile ducts.
This is often called Regurgitation Jaundice.
Q5. Conjugated Hyperbilirubinemia
1. Definition
It is a condition where the blood levels of conjugated (direct)
bilirubin are elevated (> 0.3 mg/dL or > 20\% of total bilirubin).
Because conjugated bilirubin is water-soluble, it is filtered by
the kidneys, resulting in bilirubinuria (dark-colored urine).
2. Pathophysiology
This occurs when there is a "blockage" in the pathway after the
bilirubin has been conjugated in the hepatocyte.
* Defective Excretion: The bilirubin is conjugated but cannot be
pumped out into the bile canaliculi.
* Obstruction: Physical blockage of the bile ducts (intrahepatic
or extrahepatic).
3. Major Causes
A. Obstructive Jaundice (Extrahepatic)
* Causes: Gallstones (cholelithiasis), carcinoma of the head of
the pancreas, or biliary atresia.
* Mechanism: The bile duct is blocked. Conjugated bilirubin
"leaks" back (regurgitates) from the liver cells into the systemic
blood circulation.
B. Genetic Disorders of Excretion
* Dubin-Johnson Syndrome: An autosomal recessive condition
caused by a mutation in the MRP2 protein (the pump that
moves conjugated bilirubin into bile).
* Characteristic: The liver turns black due to pigment
deposition.
* Rotor Syndrome: Similar to Dubin-Johnson but milder, and
the liver is not pigmented. It involves a defect in the organic
anion transporters (OATP1B1/B3).
4. Lab Findings (The Clinical Picture)
This is where the findings are the exact opposite of hemolytic
jaundice.
| Lab Test | Finding | Reason |
|---|---|---|
| Serum Bilirubin | ↑ Conjugated (Direct) | Bilirubin is
conjugated but enters blood. |
| Van den Bergh | Direct Positive | Conjugated bilirubin reacts
immediately. |
| Urine Bilirubin | Present | Water-soluble bilirubin is filtered
by kidney. |
| Urine Urobilinogen | Absent / Decreased | Bilirubin never
reaches the gut to be converted. |
| Fecal Stercobilin | Absent (Clay-colored) | No bile pigments
reach the feces. |
5. Clinical Features
* Pruritus (Itching): Due to the accumulation of bile salts in the
skin (bile salts are blocked along with the bilirubin).
* Dark Urine: Often described as "coca-cola" or tea-colored
urine.
* Pale Stools: Because stercobilin is missing.
 * Malabsorption: Lack of bile in the gut leads to poor
absorption of fat and Vitamin K, potentially causing bleeding
tendencies (increased Prothrombin Time).
Flowchart of Conjugated Hyperbilirubinemia
Exam Tip: If you see "Direct Van den Bergh Positive" and "Dark
Urine" in a clinical case, think Conjugated Hyperbilirubinemia
immediately.

Q6. Differential Diagnosis of Jaundice

1. Introduction
Jaundice (Icterus) is the yellowish discoloration of skin and
sclera due to serum bilirubin levels exceeding 2 mg/dL. It is
clinically classified into three types based on the site of
pathology: Pre-hepatic, Hepatic, and Post-hepatic.
2. Differential Diagnosis Table
| Feature | Pre-Hepatic (Hemolytic) | Hepatic (Hepatocellular) |
Post-Hepatic (Obstructive) |
|---|---|---|---|
| Common Cause | Hemolysis, Malaria | Viral Hepatitis,
Cirrhosis | Gallstones, Cancer Pancreas |
| Bilirubin Type | Unconjugated ↑↑ | Both (Mixed) |
Conjugated ↑↑ |
| Van den Bergh | Indirect Positive | Biphasic | Direct Positive |
| Urine Bilirubin | Absent (Acholuric) | Present | Present (High)
|
| Urine Urobilinogen | Increased | Decreased/Normal | Absent
|
| Stool Color | Dark (Pleiochromic) | Normal / Light | Clay-
colored |
| Pruritus (Itching) | Absent | Occasional | Severe (due to bile
salts) |
| Serum Enzymes | Normal | ALT & AST ↑↑ | ALP & GGT ↑↑
|
3. Key Laboratory Highlights
A. Van den Bergh Reaction
* Direct: Conjugated bilirubin reacts immediately with
Diazotized Sulfanilic Acid.
* Indirect: Unconjugated bilirubin needs alcohol to react.
* Biphasic: Seen in Hepatic jaundice where both types are
elevated.
B. Serum Enzymes (Crucial for Marks)
 * In Hepatocellular jaundice, the liver cells are damaged, so
"leaking" enzymes like ALT (SGPT) and AST (SGOT) are very
high.
* In Obstructive jaundice, the blockage triggers the synthesis of
Alkaline Phosphatase (ALP) and GGT in the bile duct lining,
making these the primary markers.
4. Diagnostic Flowchart
* Check Serum Bilirubin: If >2 mg/dL \to Jaundice confirmed.
* Check Urine: * No Bilirubin + High Urobilinogen \to
Hemolytic.
* Bilirubin Present + No Urobilinogen \to Obstructive.
* Check Enzymes:
* High ALT/AST \to Hepatic.
* High ALP \to Post-hepatic.
Summary for Exam
When writing this, mention that Post-hepatic patients often
have a prolonged Prothrombin Time (PT) because the absence
of bile prevents Vitamin K absorption. This shows the examiner
you understand the clinical implications.

1. Dubin-Johnson Syndrome
The Defect: There is a specific "pump" called MRP2 (Multidrug
Resistance-associated Protein 2). Its job is to pump conjugated
bilirubin out of the liver cell into the bile duct. In this syndrome,
that pump is missing.
What happens? The "packaged" (conjugated) bilirubin builds up
inside the liver cell. Since it can't go into the bile, it leaks
backward into the blood.
Special Feature (Very Important for Exams): The liver cells also
fail to export other pigments, so the liver turns black.
Key Point: Conjugated Bilirubin ↑ | Black Liver | Normal Life
Expectancy.
2. Rotor Syndrome
The Defect: This is very similar, but it involves the "re-uptake"
transporters (OATP1B1 and OATP1B3).
What happens? Bilirubin gets conjugated, but it "slips out" and
the liver can't pull it back in to send it to the bile.
The Difference: In Rotor Syndrome, the liver is NOT black. It
looks completely normal under a microscope.
Key Point: Conjugated Bilirubin ↑ | Normal colored liver.

Ratio = AST / ALT

In most Viral Hepatitis cases: ALT (SGPT) is higher than AST
(SGOT).
In Alcoholic Liver Disease: AST (SGOT) is usually much higher
than ALT (SGPT)

Q7. Acute Intermittent Porphyria (AIP)

It’s often nicknamed the "Little Mimicker" because its

symptoms look like a surgical emergency (appendicitis) or a
psychiatric breakdown.1. Definition
AIP is an autosomal dominant metabolic disorder characterized
by a partial deficiency of the enzyme PBG Deaminase. It is the
most common of the hepatic porphyrias and presents with
periodic "attacks" rather than constant symptoms.
2. Biochemical Defect
* Enzyme Deficient: Porphobilinogen (PBG) Deaminase (also
known as Uroporphyrinogen I Synthase).
* Metabolic Result: The block in the pathway leads to the
massive accumulation of the precursors:
* \delta-Aminolevulinic Acid (ALA)
* Porphobilinogen (PBG)
* These precursors are excreted in excess in the urine.
3. Pathogenesis of Symptoms
The symptoms are primarily neurovisceral (affecting nerves and
internal organs).
* ALA is neurotoxic: It is structurally similar to GABA (a
neurotransmitter) and interferes with nerve function.
* Heme Deficiency: Since the pathway is blocked, the liver
lacks heme, which removes the "negative feedback" on the first
enzyme, ALA Synthase. This causes the body to produce even
more toxic ALA and PBG, making the attack worse.
4. Clinical Features (The 5 P's)
To remember the symptoms for your exam, use this mnemonic:
* Pain in Abdomen: Severe, colicky, but the abdomen is "soft"
(no inflammation).
* Psychological Disturbance: Confusion, anxiety, or "madness."
* Polyneuropathy: Muscle weakness or paralysis.
* Purple/Port-wine Urine: Urine darkens when exposed to light
(PBG oxidizes to Porphobilin).
* Precipitated by Drugs: Attacks are triggered by alcohol,
barbiturates, or fasting.
> Note: AIP is NOT associated with photosensitivity (skin
blisters). This distinguishes it from other porphyrias.
>
5. Laboratory Diagnosis
* Urine Examination:
* Ehrlich’s Test: Positive for PBG.
* Fresh Urine: May look normal, but turns dark red/purple on
standing.
* Biochemical Assay: Increased levels of ALA and PBG in urine
and plasma.
* Enzyme Assay: Decreased activity of PBG Deaminase in Red
Blood Cells.
6. Management and Treatment
* Avoid Triggers: Stop all "porphyrinogenic" drugs
(Barbiturates, Sulfa drugs).
* Glucose Loading: High carbohydrate intake (IV Dextrose)
helps suppress the enzyme ALA Synthase.
* Hematin/Heme Arginate Therapy: Administering heme
directly provides "negative feedback" to shut down the
overactive pathway.
* Pain Management: Using safe analgesics like Opiates.
Summary Flowchart for Marks
Exam Tip: If a case study mentions a patient with "recurrent
abdominal pain and dark urine whose symptoms get worse
after taking sleeping pills (barbiturates)," the answer is almost
always AIP.

Q8. Catabolism of Hemoglobin

1. Site of Catabolism
Hemoglobin catabolism occurs in the Reticuloendothelial
System (RES), primarily in the Spleen (the "graveyard of RBCs"),
Liver, and Bone Marrow.
2. Breakdown of the Hemoglobin Molecule
The average lifespan of an RBC is 120 days. When they become
fragile, they are trapped in the spleen and broken down into
three components:
* Globin: Broken down into Amino acids, which return to the
body's pool for protein synthesis.
* Iron (Fe^{2+}): Released and stored as Ferritin or transported
by Transferrin to be reused.
 * Heme: This is the part that undergoes further catabolism to
form bile pigments.
3. The Heme Degradation Pathway (Step-by-Step)
Step 1: Formation of Biliverdin
The enzyme Heme Oxygenase breaks the \alpha-methenyl
bridge of the porphyrin ring.
* Requirements: O_2 and NADPH.
* Products: Biliverdin (a green pigment), Carbon Monoxide
(CO), and Iron.
* Clinical Note: This is the only reaction in the human body that
produces Carbon Monoxide naturally.
Step 2: Formation of Bilirubin
Biliverdin is reduced by the enzyme Biliverdin Reductase.
* Requirement: NADPH.
* Product: Unconjugated Bilirubin (Yellow-orange pigment).
Step 3: Transport and Conjugation
* Bilirubin is water-insoluble, so it binds to Albumin to travel to
the liver.
* In the liver, it is conjugated with Glucuronic acid by the
enzyme UDP-Glucuronosyltransferase to become water-soluble
Bilirubin Diglucuronide.
Step 4: Intestinal Transformation
Conjugated bilirubin is secreted into the bile and enters the
intestine.
* Bacteria act on it to form Urobilinogen (colorless).
* Urobilinogen is oxidized to Stercobilin (excreted in feces,
giving the brown color) or Urobilin (excreted in urine).
4. Summary Flowchart for Exams
5. Expected Points for Full Marks
* Mention the enzyme Heme Oxygenase as the rate-limiting
step of heme breakdown.
* Highlight that Iron and Globin are recycled, while the
Porphyrin ring is excreted as bilirubin.
* Specify the role of NADPH as a co-factor.

Q9. Obstructive Jaundice

1. Definition
Obstructive jaundice occurs when there is a physical hindrance
to the flow of bile from the hepatocytes to the duodenum. This
results in the "regurgitation" of conjugated bilirubin into the
bloodstream.
2. Etiology (Causes)
* Intrahepatic: Primary biliary cholangitis, drugs
(Chlorpromazine), or viral hepatitis (cholestatic phase).
* Extrahepatic:
* Gallstones in the common bile duct (Choledocholithiasis).
* Carcinoma of the head of the pancreas (causes "painless
jaundice").
* Biliary atresia (in newborns).
3. Pathophysiology
* Blockage: Bile cannot reach the intestine.
* Back-pressure: Conjugated bilirubin and bile salts build up in
the bile canaliculi.
* Regurgitation: The pressure causes these components to leak
into the hepatic sinusoids and enter the systemic circulation.
* Absence in Gut: Because no bile reaches the gut, there is no
formation of Urobilinogen or Stercobilin.
4. Biochemical and Clinical Features
| Feature | Finding | Reason |
|---|---|---|
| Serum Bilirubin | ↑ Conjugated (Direct) | Direct bilirubin
leaks into blood. |
| Van den Bergh | Direct Positive | Conjugated bilirubin reacts
immediately. |
| Urine | Dark / Tea-colored | Conjugated bilirubin is water-
soluble and excreted. |
| Stools | Clay-colored (Acholous) | Absence of Stercobilin. |
| Pruritus | Severe Itching | Deposition of Bile Salts in the skin.
|
| Urine Urobilinogen | Absent | No bilirubin reaches the gut for
conversion. |
| Enzymes | ↑↑ ALP and GGT | Obstruction induces these
enzymes in the bile ducts. |
5. Complications: Malabsorption
Since bile is necessary for the emulsification and absorption of
fats:
* Steatorrhea: Foul-smelling, fatty stools.
 * Vitamin K Deficiency: Leads to decreased synthesis of clotting
factors (II, VII, IX, X), resulting in a prolonged Prothrombin Time
(PT).
* Exam point: This can be corrected by parenteral (injection)
Vitamin K.
6. Courvoisier's Law (Clinical Note)
In a patient with jaundice, if the gallbladder is palpable
(enlarged), the obstruction is likely due to a tumor (like cancer
of the pancreas) rather than a stone, because stones usually
cause a scarred, shrunken gallbladder.

Q10. Physiological Jaundice of the Newborn

1. Definition
Physiological jaundice is a mild, transient unconjugated
hyperbilirubinemia that occurs in almost all newborns. It
typically appears after 24 hours of life, peaks between the 3rd
and 5th day, and subsides by the 10th day.
2. Pathophysiology (Causes)
The "immaturity" of the neonatal liver leads to this condition
through four main mechanisms:
 * Increased Bilirubin Production: Neonates have a higher RBC
mass and a shorter RBC lifespan (approx. 70–90 days compared
to 120 days in adults).
* Deficient Transport: Low levels of Albumin in the blood limit
the transport of unconjugated bilirubin.
* Defective Conjugation (Main Cause): The enzyme UDP-
Glucuronosyltransferase (UGT) has very low activity in
newborns. It takes about 1–2 weeks for this enzyme to reach
adult levels.
* Low Intracellular Proteins: Low levels of Ligandin (Y-protein)
in hepatocytes reduce the uptake of bilirubin from the blood.
3. Clinical Criteria (Important for Marks)
To be called "Physiological," it must meet these criteria:
* Appears after 24 hours of birth.
* Serum bilirubin usually does not exceed 12–15 mg/dL.
* The rate of rise is slow (< 5 mg/dL per day).
* Disappears by the 10th to 14th day in full-term infants.
* The baby is otherwise healthy and feeding well.
4. Complication: Kernicterus
If bilirubin levels exceed the binding capacity of albumin (>20
mg/dL), free unconjugated bilirubin (which is lipophilic) crosses
the Blood-Brain Barrier.
* It deposits in the Basal Ganglia.
* It causes permanent neurological damage, seizures, and
mental retardation.
5. Management
* Phototherapy (Blue-Green Light):
* Mechanism: It converts bilirubin into Lumirubin (a water-
soluble structural isomer) through a process called photo-
isomerization.
* Advantage: Lumirubin can be excreted in urine and bile
without needing conjugation by the liver.
* Exchange Transfusion: Performed if bilirubin levels reach
dangerous limits to prevent Kernicterus.
* Phenobarbital: Sometimes used to induce (stimulate) the
production of the UGT enzyme.
6. Differential Diagnosis (Physiological vs. Pathological)
| Feature | Physiological | Pathological |
|---|---|---|
| Onset | After 24 hours | Within first 24 hours |
| Duration | Lasts < 10 days | Lasts > 2 weeks |
| Bilirubin Type | Unconjugated | Can be both |
| Treatment | Usually none or Phototherapy | Often requires
aggressive therapy |

Q11. Thalassemia
1. Definition
Thalassemia is a group of hereditary hemolytic anemias
characterized by the reduced or absent synthesis of one or
more of the globin chains (\alpha or \beta) of hemoglobin.
* Unlike Sickle Cell Anemia (which is a qualitative defect),
Thalassemia is a quantitative defect.
2. Classification
It is classified based on which globin chain is affected:
* \alpha-Thalassemia: Decreased synthesis of \alpha-globin
chains.
* \beta-Thalassemia: Decreased synthesis of \beta-globin
chains.
3. \beta-Thalassemia (The more common clinical type)
Caused by mutations (usually point mutations) in the \beta-
globin gene on Chromosome 11.
Types:
* \beta-Thalassemia Minor (Trait): Only one gene is defective (\
beta / \beta^+). The patient is usually asymptomatic or has mild
anemia.
* \beta-Thalassemia Major (Cooley's Anemia): Both genes are
defective (\beta^0 / \beta^0). Symptoms appear after 6 months
of age when HbF (fetal hemoglobin) normally switches to HbA.
Pathophysiology:
* Reduced HbA synthesis: Leads to Microcytic Hypochromic
Anemia.
* \alpha-chain Precipitation: Since \beta-chains are missing,
the excess \alpha-chains accumulate and precipitate in the
RBCs.
* Ineffective Erythropoiesis: These precipitates damage the
RBC membrane, leading to their destruction in the bone
marrow and spleen (hemolysis).
4. \alpha-Thalassemia
Caused by the deletion of one or more of the four \alpha-globin
genes on Chromosome 16.
| No. of Genes Deleted | Clinical Name | Features |
|---|---|---|
| 1 Gene | Silent Carrier | Asymptomatic. |
| 2 Genes | \alpha-Thalassemia Trait | Mild anemia. |
| 3 Genes | HbH Disease | Excess \beta-chains form tetramers
(\beta_4) called HbH. |
| 4 Genes | Hydrops Fetalis | No \alpha-chains. Excess \gamma-
chains form tetramers (\gamma_4) called Hb Barts.
Incompatible with life (fetal death). |
5. Laboratory Diagnosis
* Peripheral Smear: Microcytic, hypochromic RBCs with Target
Cells and nucleated RBCs.
* Hb Electrophoresis (Gold Standard):
* In \beta-Thal Major: HbA is nearly absent. HbF is
significantly increased (30\text{--}90\%).
* Reticulocyte Count: Increased (due to hemolysis).
* Iron Profile: High Serum Iron and Ferritin (due to repeated
transfusions and hemolysis).
6. Clinical Features
* Anemia: Severe, starting in infancy.
* Splenomegaly: Due to excessive RBC destruction.
* Skeletal Changes: Bone marrow expansion leads to
"Chipmunk facies" (prominent cheekbones) and a "Hair-on-
end" appearance on skull X-ray.
* Iron Overload (Hemosiderosis): Due to frequent blood
transfusions, leading to damage to the heart, liver, and
endocrine glands.
7. Management
* Regular Blood Transfusions: To maintain Hb levels.
* Iron Chelation Therapy: Using Desferrioxamine to remove
excess iron.
* Bone Marrow Transplantation: The only curative treatment.
Summary Comparison for Exam:
* Sickle Cell: Qualitative change (Glutamate \to Valine).
* Thalassemia: Quantitative change (Less/No production of
chains).

Q12. 2,3-Bisphosphoglycerate (2,3-BPG)

1. Introduction
2,3-BPG is a small organic molecule found in high
concentrations within Red Blood Cells (RBCs). It is a crucial
allosteric effector that regulates the affinity of hemoglobin for
oxygen.
2. Synthesis (Rapoport-Luebering Cycle)
In most cells, 1,3-BPG (from glycolysis) is converted to 3-
phosphoglycerate to produce ATP. However, in RBCs, about 15-
25% of this 1,3-BPG is diverted to form 2,3-BPG.
* Enzyme: BPG Mutase (converts 1,3-BPG → 2,3-BPG).
* Significance: This bypasses an ATP-producing step, meaning
RBCs sacrifice energy (ATP) to produce this regulator.
3. Mechanism of Action
Hemoglobin exists in two states:
* T-state (Tense): Low affinity for oxygen (unloaded).
* R-state (Relaxed): High affinity for oxygen (loaded).
* The "Pocket" Binding: 2,3-BPG is a highly negatively charged
molecule. It binds to a positively charged pocket between the
two beta-chains of Deoxy-Hb (T-state).
* Stabilization: By binding there, it stabilizes the T-state,
making it harder for oxygen to stay attached.
* Result: It pushes the Oxygen Dissociation Curve (ODC) to the
RIGHT, facilitating the release of oxygen to the tissues.
4. Factors Increasing 2,3-BPG Levels
The body increases 2,3-BPG production when tissues are
starving for oxygen:
* High Altitude: At high altitudes, PO_2 is low. Increased 2,3-
BPG helps Hb "drop off" more oxygen at the tissues despite the
low intake.
* Chronic Anemia: To compensate for fewer RBCs, the
remaining cells produce more 2,3-BPG to maximize oxygen
delivery.
* Chronic Obstructive Pulmonary Disease (COPD): Due to poor
lung oxygenation.
5. Clinical Significance
A. Fetal Hemoglobin (HbF) and 2,3-BPG
* HbF has gamma (\gamma) chains instead of beta (\beta)
chains.
* The \gamma-chains have fewer positive charges in the
central pocket.
* Therefore, 2,3-BPG binds poorly to HbF.
* Result: HbF has a higher affinity for oxygen than adult HbA.
This allows the fetus to "pull" oxygen from the mother's blood
across the placenta.
B. Stored Blood
* In stored blood (bank blood), 2,3-BPG levels decrease over
time.
* If such blood is transfused, it "holds onto" oxygen too tightly
and doesn't deliver it to the patient's tissues effectively.
* Note: Additives like Inosine are used to help restore 2,3-BPG
levels in stored blood.
Summary Table for Marks
| Aspect | Finding / Effect |
|---|---|
| Binding Site | Between \beta-chains of Deoxy-Hb |
| State Stabilized | T-state (Tense) |
| Affinity for O_2 | Decreased |
| ODC Curve Shift | Shift to the Right |
| HbF Affinity | Higher (due to low 2,3-BPG binding) |
Q13. Abnormal Hemoglobins (Hemoglobinopathies)
1. Definition
Abnormal hemoglobins, or Hemoglobinopathies, are a group of
genetic disorders caused by structural variations in the globin
chains. These usually result from a single amino acid
substitution (point mutation) in the \alpha or \beta globin
chains.
2. Classification
They are classified based on the clinical effect of the mutation:
A. Structural Variants (Most Common)
* HbS (Sickle Cell Hemoglobin): Substitution of Valine for
Glutamate at the 6th position of the \beta-chain.
* HbC: Substitution of Lysine for Glutamate at the 6th position
of the \beta-chain.
* HbE: Common in Southeast Asia; substitution of Lysine for
Glutamate at the 26th position of the \beta-chain.
B. Altered Oxygen Affinity
* Hb Chesapeake: High oxygen affinity; the hemoglobin doesn't
release oxygen easily, leading to polycythemia (excess RBCs).
* Hb Kansas: Low oxygen affinity; results in cyanosis.
C. Variants that cause Methemoglobinemia
 * Hb M (Hemoglobin M): Mutations (usually Histidine \to
Tyrosine) that stabilize iron in the Ferric (Fe^{3+}) state. Ferric
iron cannot bind oxygen, leading to "Chocolate cyanosis."
3. Detailed Look: Hemoglobin S (HbS)
Since this is the most high-yield abnormal hemoglobin, ensure
you include these specific points:
* The Mutation: \beta-chain, 6th position: Glutamic acid
(polar) \to Valine (non-polar).
* Molecular Consequence: In the deoxygenated state, the non-
polar Valine creates a "sticky patch" on the surface of the
hemoglobin.
* Polymerization: These sticky patches cause HbS molecules to
link together, forming long, insoluble fibers.
* Sickling: These fibers distort the RBC into a crescent or sickle
shape.
* Clinical Effect: Sickled cells are fragile (hemolysis) and stiff
(blocking small capillaries, causing "Vaso-occlusive crisis").
4. Detailed Look: Hemoglobin M (HbM)
* Mechanism: The mutation involves the proximal or distal
Histidine of the heme-binding pocket.
 * Result: Iron is oxidized to Fe^{3+}. Methemoglobin cannot
carry oxygen.
* Clinical Sign: Patients appear blue (Cyanosis) but do not
respond to oxygen therapy.
5. Laboratory Diagnosis of Abnormal Hemoglobins
To score full marks, mention how we detect these in the lab:
* Hemoglobin Electrophoresis (at Alkaline pH): This is the most
important test. Because the amino acid substitutions change
the electrical charge of the hemoglobin, they move at different
speeds in an electric field.
* Mnemonic for Speed (Fastest to Slowest): A F S C ("A Fat
Slow Cat").
* Solubility Test (for HbS): Deoxygenated HbS is insoluble in
concentrated phosphate buffers and produces turbidity.
* High-Performance Liquid Chromatography (HPLC): The
modern "Gold Standard" for quantifying different Hb variants.
6. Summary Table for Exams
| Abnormal Hb | Mutation (\beta-chain) | Key Feature |
|---|---|---|
| HbS | 6th Glu \to Val | Sickling & Infarction |
| HbC | 6th Glu \to Lys | Mild Hemolysis |
| HbE | 26th Glu \to Lys | Microcytic Anemia |
| HbM | His \to Tyr | Methemoglobinemia (Cyanosis) |

Q14. Sickle Cell Anemia (HbS)

1. Definition
Sickle cell anemia is an autosomal recessive genetic blood
disorder characterized by the production of an abnormal
hemoglobin variant called HbS. It results in RBCs assuming a
rigid, sickle-like shape under conditions of low oxygen tension.
2. Molecular Basis (The Genetic Defect)
The defect is a Point Mutation in the \beta-globin gene located
on Chromosome 11.
* Substitution: The amino acid Glutamic acid
(polar/hydrophilic) is replaced by Valine
(non-polar/hydrophobic) at the 6th position of the \beta-globin
chain.
* Notation: \beta^6 \text{ Glu} \to \text{Val}.
3. Pathophysiology (The Sickling Process)
* Deoxygenation: When HbS gives up oxygen (in tissues), the
Valine at the 6th position is exposed on the surface.
* Sticky Patches: Valine is hydrophobic and creates a "sticky
patch." This patch fits into a complementary pocket on a
neighboring HbS molecule.
* Polymerization: These molecules link together to form long,
insoluble helical polymers (fibers).
* Distortion: These fibers push against the RBC membrane,
changing the flexible biconcave disc into a rigid Sickle shape.
* Irreversibility: Initially, sickling is reversible with oxygen.
However, after repeated cycles, the membrane is damaged,
and the cell becomes a "Permanently Sickled Cell."
4. Clinical Manifestations
A. Hemolytic Anemia
Sickled RBCs are fragile. Their lifespan is reduced from 120 days
to 10–20 days. This leads to chronic jaundice and gallstones.
B. Vaso-occlusive Crises
The rigid sickle cells cannot pass through narrow capillaries.
They "log-jam" the vessels, leading to:
* Dactylitis: Painful swelling of hands and feet (Hand-foot
syndrome) in children.
 * Splenic Infarction: Repeated blockages lead to the spleen
shrinking and scarring (Autosplenectomy).
* Acute Chest Syndrome: Blockage in the lung vessels (a
leading cause of death).
C. Heterozygote Advantage
Individuals with Sickle Cell Trait (HbAS) are protected against
Falciparum Malaria. The parasite cannot thrive in a cell that
sickles and is cleared by the spleen prematurely.
5. Laboratory Diagnosis
* Peripheral Smear: Presence of Sickle-shaped cells and Target
cells.
* Sickling Test: Adding a reducing agent like Sodium
Metabisulfite to a blood drop induces sickling, which can be
seen under a microscope.
* Solubility Test: HbS is insoluble in concentrated phosphate
buffer (solution becomes turbid).
* Hb Electrophoresis: * HbSS (Disease): No HbA, mostly HbS.
* HbAS (Trait): Both HbA and HbS present (HbA > HbS).
6. Management
* Hydration and Oxygen: To prevent sickling.
 * Hydroxyurea: A drug that increases the production of HbF
(Fetal Hemoglobin). Since HbF does not have \beta-chains, it
cannot sickle and prevents HbS from polymerizing.
* Prophylactic Antibiotics: To prevent infections due to loss of
splenic function.

Q15. Disorders of Heme Catabolism

1. Introduction
Disorders of heme catabolism arise when there is a breakdown
in the pathway that converts heme into bilirubin and eventually
excretes it. These disorders manifest as Hyperbilirubinemia
(elevation of bilirubin in the blood), which clinically presents as
Jaundice.
2. Classification of Disorders
The disorders are broadly divided into Genetic (Hereditary) and
Acquired.
3. Hereditary Unconjugated Hyperbilirubinemia
These occur due to defects in the uptake or conjugation of
bilirubin in the liver.
* Crigler-Najjar Syndrome Type I: * Defect: Complete absence
of the enzyme UDP-Glucuronosyltransferase (UGT).
 * Clinical: Severe jaundice (>20 mg/dL); usually leads to
Kernicterus and death in infancy.
* Crigler-Najjar Syndrome Type II (Arias Syndrome):
* Defect: Partial deficiency of UGT (\sim 10\% activity
remains).
* Clinical: Less severe; responds well to Phenobarbital (which
induces the enzyme).
* Gilbert’s Syndrome:
* Defect: Mild reduction in UGT activity (\sim 30\% of
normal).
* Clinical: Mostly asymptomatic. Jaundice appears only during
periods of stress, fasting, or illness.
4. Hereditary Conjugated Hyperbilirubinemia
In these cases, the liver conjugates bilirubin, but cannot export
it into the bile.
* Dubin-Johnson Syndrome:
* Defect: Mutation in the MRP2 protein (the canalicular multi-
specific organic anion transporter).
* Sign: The liver develops a characteristic black pigmentation
due to the accumulation of metabolic byproducts.
* Rotor Syndrome:
 * Defect: Defect in the organic anion transporters
(OATP1B1/B3) responsible for the re-uptake of bilirubin.
* Difference: Similar to Dubin-Johnson, but the liver is not
pigmented.
5. Acquired Disorders
* Neonatal (Physiological) Jaundice: Due to the temporary
immaturity of the neonatal liver (low UGT levels).
* Toxic Hyperbilirubinemia: Liver damage caused by toxins like
Carbon tetrachloride, Chloroform, or Acetaminophen
(Paracetamol) overdose.
* Obstruction: Acquired blockage of the bile duct by Gallstones
or Carcinoma of the head of the pancreas.
6. Differential Lab Diagnosis (The "Marks Booster" Table)
| Disorder | Bilirubin Type | Urine Bilirubin | Van den Bergh |
|---|---|---|---|
| Hemolysis | Unconjugated ↑ | Absent | Indirect Positive |
| Gilbert's | Unconjugated ↑ | Absent | Indirect Positive |
| Dubin-Johnson | Conjugated ↑ | Present | Direct Positive |
| Obstruction | Conjugated ↑ | Present | Direct Positive |
Here is your 1-page Heme & Hemoglobin Cheat Sheet. This is
designed to give you the highest marks with the shortest
amount of reading.
I. Heme Synthesis & Porphyrias
| Condition | Deficient Enzyme | Key Accumulation | Clinical
Hallmark |
|---|---|---|---|
| Acute Intermittent Porphyria (AIP) | PBG Deaminase | ALA &
PBG | Port-wine urine, No photosensitivity. |
| Porphyria Cutanea Tarda | UROD | Uroporphyrin |
Photosensitivity (skin blisters). |
| Lead Poisoning | ALAD & Ferrochelatase | ALA &
Protoporphyrin | Basophilic stippling, Blue gums. |
II. Heme Catabolism & Jaundice
The "Big Three" Types
* Pre-Hepatic (Hemolytic): ↑ Unconjugated Bilirubin | Dark
Stools | Indirect Van den Bergh.
* Hepatic (Hepatocellular): ↑ Both Bilirubins | ↑ ALT/AST |
Biphasic Van den Bergh.
* Post-Hepatic (Obstructive): ↑ Conjugated Bilirubin | Clay
Stools | ↑ ALP & GGT | Direct Van den Bergh.
The Genetic "Jaundice" Table
| Syndrome | Defect | Bilirubin Type | Liver Appearance |
|---|---|---|---|
| Crigler-Najjar I | Zero UGT enzyme | Unconjugated | Normal
(Fatal) |
| Gilbert’s | Low UGT activity | Unconjugated | Normal (Stress-
induced) |
| Dubin-Johnson | MRP2 (Excretory pump) | Conjugated | Black
Liver |
| Rotor | OATP (Uptake/Transport) | Conjugated | Normal |
III. Abnormal Hemoglobins
Sickle Cell Anemia (HbS)
* Mutation: \beta^6 Glutamate \rightarrow Valine.
* Mechanism: Deoxygenation \rightarrow HbS Polymerization \
rightarrow Sickling.
* Key Drug: Hydroxyurea (Increases HbF).
Thalassemia (The "Quantitative" Defect)
* \alpha-Thal: Deletion of \alpha-genes (Hb Barts = 4 genes
deleted).
* \beta-Thal: Mutation in \beta-genes (HbF ↑↑ in Major).
IV. Critical Biochemistry "Must-Knows"
* Rate Limiting Enzyme (Heme Synthesis): ALA Synthase
(Requires Vitamin B6).
* Rate Limiting Enzyme (Heme Breakdown): Heme Oxygenase.
* 2,3-BPG: Stabilizes T-state, shifts ODC to the Right, helps
oxygen release.
* Phototherapy: Converts bilirubin to Lumirubin (water-
soluble).
> Pro-Tip for Paper Presentation: > When you see a question on
Jaundice, always write down the Van den Bergh Reaction
results (Direct, Indirect, or Biphasic). It’s an instant point-
booster.